98
Participants
Start Date
April 14, 2011
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
atorvastatin
10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
atorvastatin
Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
placebo for atorvastin
One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
Cornell CRS (7804), New York
NY Univ. HIV/AIDS CRS (401), New York
AIDS Care CRS (1101), Rochester
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787), Rochester
Pitt CRS (1001), Pittsburgh
Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia
Georgetown University CRS (GU CRS) (1008), Washington D.C.
Virginia Commonwealth Univ. Medical Ctr. CRS (31475), Richmond
Unc Aids Crs (3201), Chapel Hill
Duke Univ. Med. Ctr. Adult CRS (1601), Durham
31788 Alabama CRS, Birmingham
The Ohio State Univ. AIDS CRS (2301), Columbus
Case CRS (2501), Cleveland
Metro Health CRS (2503), Cleveland
Univ. of Cincinnati CRS (2401), Cincinnati
Wayne State Univ. CRS (31478), Detroit
Henry Ford Hosp. CRS (31472), Detroit
Northwestern University CRS (2701), Chicago
Washington U CRS (2101), St Louis
Houston AIDS Research Team CRS (31473), Houston
University of Colorado Hospital CRS (6101), Aurora
UCLA CARE Center CRS (601), Los Angeles
Harbor-UCLA Med. Ctr. CRS (603), Torrance
Ucsd, Avrc Crs (701), San Diego
University of Washington AIDS CRS (1401), Seattle
Massachusetts General Hospital ACTG CRS (101), Boston
Brigham and Women's Hosp. ACTG CRS (107), Boston
Beth Israel Deaconess Med. Ctr., ACTG CRS (103), Boston
Cooper Univ. Hosp. CRS (31476), Camden
New Jersey Medical School-Adult Clinical Research Ctr. CRS (31486), Newark
Puerto Rico-AIDS CRS (5401), San Juan
Collaborators (1)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Pfizer
INDUSTRY
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK